<DOC>
	<DOCNO>NCT00003560</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine docetaxel carboplatin treat patient stage III stage IV ovarian cancer , fallopian tube cancer , primary peritoneal cancer .</brief_summary>
	<brief_title>Docetaxel Plus Carboplatin Treating Patients With Stage III Stage IV Ovarian , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate response rate , duration response , progression-free overall survival previously untreated patient suboptimally debulked stage III stage IV ovarian carcinoma , fallopian tube carcinoma , papillary serous cancer uterus , primary peritoneal carcinoma treat docetaxel carboplatin . - Evaluate feasibility toxicity regimen patient . - Evaluate effect regimen quality life patient . OUTLINE : This open-label study . Patients receive docetaxel IV 1 hour carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Quality life assess prior therapy every 3 course chemotherapy . PROJECTED ACCRUAL : Approximately 14-40 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm previously untreated ovarian cancer , fallopian tube carcinoma , papillary serous cancer uterus , primary peritoneal carcinoma Suboptimally debulked stage III suboptimally optimally debulked stage IV Measurable evaluable disease CNS lesion , lytic bone lesion , radiate lesion ( unless document progression radiotherapy ) consider measurable CA 125 level 49 units/mL absence cirrhosis nonmalignant gross ascites consider evaluable Ineligible highpriority national institutional study PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 01 Life expectancy : More 2 month Hematopoietic : WBC great 3,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT and/or SGPT le 2.5 time ULN OR SGOT and/or SGPT great 2.5 time ULN alkaline phosphatase great ULN OR Alkaline phosphatase great 4 time ULN SGOT and/or SGPT great ULN No SGOT and/or SGPT great 1.5 time ULN alkaline phosphatase great 2.5 time ULN Alkaline phosphatase le 350 U/L Renal : BUN le 1.5 time normal Creatinine le 1.5 time ULN Other : No malignancy within past 5 year except curatively treat carcinoma situ cervix skin cancer No serious medical psychiatric illness Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : No concurrent hormone therapy Radiotherapy : See Disease Characteristics No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>endometrial papillary serous carcinoma</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>